Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab.The revenue from the shots met Moderna's forecast for the year, even as sales plummeted from the more than $18 billion the company booked in 2022. Moderna's announcement, which came ahead of its presentation at the annual JPMorgan Healthcare Conference, shows the steep drop in demand for Covid products last year as cases and public conc ...

Jelena Stanojkovic/iStock via Getty Images At a Glance Delving into Moderna's (NASDAQ:MRNA) trajectory, my earlier analysis shed light on its eclectic project range. This spectrum spans from oncology to infectious diseases, with notable breakthroughs in RSV and flu vaccines. Moderna has since leaped forward, especially with mRNA-1083. This vaccine, both innovative and dual-purpose, targets COVID-19 and flu. It's now in Phase 3, with approval expected in 2025. However, it's not all smooth sailing. The pa ...

The most recent trading session ended with Moderna (MRNA) standing at $108.66, reflecting a +0.07% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.34%. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, lost 0.56%.The biotechnology company's stock has climbed by 34.72% in the past month, exceeding the Medical sector's gain of 5.72% and the S&P 500's gain of 2.56%.Market participants will be closely following the financial results of Moderna ...

Shares of Moderna (MRNA) witnessed a significant increase of more than 13% on Tuesday, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC. The upgrade is based on the belief that Moderna, a Covid vaccine manufacturer, could potentially introduce five new products to the market by 2026.Challenging 2023 for ModernaThe upgrade comes after a challenging year in 2023 for Moderna, a year in which its sole commercially available product was the Covid vaccine. The company's sto ...

Shares of COVID-19 vaccine maker Moderna (MRNA) rose 13.1% on Jan 2, after analysts at Oppenheimer recently upgraded the stock’s recommendation to Outperform, with a price target of $142 per share.Per the Oppenheimer analysts, Moderna could become ‘a five-product commercial company by 2026’. These analysts were encouraged by Moderna’s upcoming product launches over the next 12 to 18 months, which are expected to boost sales in 2025 and positive pipeline expectations.Over the next two years, Oppenheimer anal ...

Moderna (MRNA) shares soared 13.1% in the last trading session to close at $112.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.5% gain over the past four weeks.Share prices surged after analysts at Oppenheimer recently upgraded the stock’s recommendation to Outperform. Per these analysts, Moderna could become ‘a five-product commercial company by 2026’. These analysts were encouraged by Moderna’s upcoming product launches ...

Key TakeawaysModerna Inc. Chief Executive Officer (CEO) Stephane Bancel said Tuesday the vaccine maker expects sales to increase in 2025.Oppenheimer & Co. securities analysts upgraded the stock to "outperform," saying they expect the company will have five products on the market by 2026.Shares of Moderna, which struggled in 2023 as COVID-19 vaccine demand waned, jumped Tuesday on the news.Moderna Inc. (MRNA) shares soared 15% Tuesday as the vaccine maker got two pieces of positive news.First, Chief Executiv ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Moderna Inc.’s stock soared 10% Tuesday to lead S&P 500 index gainers, after Oppenheimer upgraded the stock to the equivalent of buy and said it expects the biotech to have five products approved by 2026.Analysts led by Hartaj Singh upgraded the stock MRNA, +11.61% to outperform from perform and said it expects it to perform better this year than the dismal showing recorded in 2023. The company currently has just one approved product, its mRNA-based COVID-19 vaccine, which has already passed peak sales. Bu ...

Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts. ...